Literature DB >> 1467833

Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

C M Herd1, D Donigi-Gale, T S Shoupe, C P Page.   

Abstract

1. Aerosol administration of platelet activating factor (PAF) (80 micrograms ml-1 for 60 min) to neonatally immunized rabbits caused bronchoconstriction which was far in excess of that produced by a comparable aerosol of bovine serum albumin (BSA), the carrier molecule for PAF. Bronchoconstriction of a similar magnitude was elicited by PAF in immunized, sham-immunized and normal rabbits. 2. Aerosol administration of PAF to immunized rabbits induced enhanced airway responsiveness to inhaled histamine in all animals tested, 24 h and 72 h after exposure. In not all cases had airways responsiveness returned to basal levels at 1 week following PAF challenge. In contrast, following exposure of immunized rabbits to BSA, no significant changes in airway responsiveness to histamine were evident at any of the measured time points. 3. A significant increase in the total number of inflammatory cells recovered in bronchoalveolar lavage (BAL) fluid was determined 24 h and 72 h following PAF exposure in immunized rabbits. This was associated with a significant increase in the number of neutrophils and eosinophils. Similar changes were observed following exposure of PAF to normal and sham-immunized rabbits. No change in the total number of inflammatory cells was obtained in BAL after BSA challenge to immunized rabbits; however, neutrophil numbers were significantly increased. 4. PF 5901, a specific inhibitor of the 5-lipoxygenase pathway of arachidonic acid metabolism and a leukotriene D4 antagonist, at a dose of 10 mg (direct intratracheal administration) significantly inhibited the airway resistance (RL) component of the bronchoconstriction induced by PAF in neonatally-immunized rabbits. Doses of 10 mg, 3 mg and 1 mg PF 5901 (direct intratracheal administration) were sufficient to inhibit significantly the PAF-induced increase in airways responsiveness to inhaled histamine in immunized rabbits. PF 5901 however, failed to alter the pulmonary cell infiltration induced by PAF,as assessed by BAL.5. We suggest from the results of the present study that PAF induces consistent and long-lasting increases in airways responsiveness to histamine in immunized rabbits, which is mediated, at least in part, by products of the 5-lipoxygenase metabolic pathway. Furthermore, the inability of PF 5901 to inhibit the influx of inflammatory cells into the airway lumen following PAF challenge may suggest that bronchial hyperresponsiveness and cellular infiltration are not strictly associated events.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467833      PMCID: PMC1907955          DOI: 10.1111/j.1476-5381.1992.tb13415.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.

Authors:  B Samuelsson; S E Dahlén; J A Lindgren; C A Rouzer; C N Serhan
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

Review 2.  Inhibition of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

3.  Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.

Authors:  C M Hogaboam; D Donigi-Gale; T S Shoupe; E Y Bissonnette; A D Befus; J L Wallace
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

4.  The bronchoconstrictor properties of platelet-activating factor in humans.

Authors:  A H Rubin; L J Smith; R Patterson
Journal:  Am Rev Respir Dis       Date:  1987-11

5.  Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132.

Authors:  M A Kings; I Chapman; A Kristersson; S Sanjar; J Morley
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

6.  The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects.

Authors:  J P Arm; B W Spur; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1988-10       Impact factor: 10.793

7.  Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects.

Authors:  M G Kaye; L J Smith
Journal:  Am Rev Respir Dis       Date:  1990-04

8.  PAF-induced bronchial hyperresponsiveness in the rabbit: contribution of platelets and airway smooth muscle.

Authors:  A J Coyle; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

9.  Asthma as an axon reflex.

Authors:  P J Barnes
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

10.  Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man.

Authors:  K F Chung; G Dent; P J Barnes
Journal:  Thorax       Date:  1989-02       Impact factor: 9.139

View more
  4 in total

1.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

2.  Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  M Sasaki; C M Herd; C P Page
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

3.  The effect of platelet-activating factor on the responsiveness of the human nasal airway.

Authors:  C E Austin; J C Foreman
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Effect of PF 10040 on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; S A Kilfeather; S A Okiji; C P Page
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.